Jubaida Mazumder
Internal Medicine · Cleveland, OHNPI 1093475535
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $586, 2.8 times the $208 reported in 2023.
Across 46 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Octapharma USA, Inc.$146
- Lilly USA, LLC$94
- Amgen$54
- Corcept Therapeutics$51
- CSL Behring$50
- Dexcom, Inc.$48
- plus $452 from 17 others
What the payments were for
- Food & beverage$896100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Octapharma USA, Inc. | 4 | $146 |
| Lilly USA, LLC | 5 | $94 |
| Amgen | 3 | $54 |
| Corcept Therapeutics | 2 | $51 |
| CSL Behring | 2 | $50 |
| Dexcom, Inc. | 2 | $48 |
| AbbVie | 3 | $47 |
| Pfizer | 2 | $38 |
| AstraZeneca | 2 | $37 |
| Exact Sciences | 2 | $35 |
| GSK | 2 | $34 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| Mannkind Corporation | 1 | $32 |
| Merck | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Verity Pharmaceuticals Inc. | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 4 | $18 |
| Soleno Therapeutics, Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Novartis | 1 | $15 |
How this compares
$896 in reported general payments places this provider in the 70th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 25 | $179 |
| Losartan Potassium | 11 | $89 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Cleveland
- Cyrus HarrisCleveland$726K
- Marina MagreyCleveland$312K
- Joshua LonginowCleveland$241K
- Emad MansoorCleveland$219K
- Syed BukhariCleveland$165K
- Vadim KoshkinCleveland$159K
- Suresh Kumar BalasubramanianCleveland$148K
- Christine Tanaka-EspositoCleveland$123K
- Carla HarwellCleveland$75K
- Amr MohamedCleveland$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.